title: [Headache--what is the current status?].
abstract: Clinical and experimental evidence suggest, that migraine reflects a biological disorder of the brain. On the basis of a genetic predisposition, variations in internal rhythms may change the responsiveness towards external trigger factors. During the migraine attack changes occur in the cortical neuronal activity, in cerebral blood flow and in the activity of neuropeptide neurotransmitters such as substance P and calcitonin-gene-related-peptide. The consequence is an aseptic inflammation in the wall of dural arteries. Sumatriptan is a new agent which selectively acts at 5-HT-1D receptors in brain vessels and improves headache and autonomic symptoms in severe migraine attacks. Sumatriptan is also helpful in the treatment of headache attacks in cluster headache. The treatment of chronic tension-type headache requires the combination of tricyclics with behavioral techniques such as relaxation training.
authors.affiliation: Klinik und Poliklinik für Neurologie, Universität Essen.
authors.forename: H C
authors.initials: HC
authors.lastname: Diener
authors.forename: V
authors.initials: V
authors.lastname: Limmroth
mesh_terms: D000700:Analgesics / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006261:Headache / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy / Q000209:etiology*
chemical_list: D000700:Analgesics
vernacular_title: Kopfweh--wo stehen wir heute?